Výsledky vyhledávání - "Geoffrey D. Hall"

Akademický článek

Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.

Autor: Erica B Wilson, Jehan J El-Jawhari, Abbie L Neilson, Geoffrey D Hall, Alan A Melcher, Josephine L Meade, Graham P Cook

Publikováno v: PLoS ONE, Vol 6, Iss 9, p e22842 (2011)

Immune evasion is now recognized as a key feature of cancer progression. In animal models, the activity of cytotoxic lymphocytes is suppressed in the tumour microenvironment by the immunosuppressive cytokine, Transforming Growth Factor (TGF)-β. Rele

Externí odkaz: https://doaj.org/article/20d56bb28df2483d9ebfcbba024203d3

Zobrazit plný text záznamu

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Autor: Mercel Ball, James Larkin, Katie Twigger, Katie L. Newbold, Victoria Roulstone, Kevin J. Harrington, Alan Melcher, K. Mettinger, Brad Thompson, Geoffrey D. Hall, Mary Anne Lagmay Tanay, Hardev Pandha, Martin Gore, Matthew C. Coffey, John D. Chester, Kostas N. Syrigos, Eleni M. Karapanagiotou, Christopher M. Nutting, Richard G. Vile

Publikováno v: Clinical Cancer Research. 18:2080-2089

Purpose: Reovirus type 3 Dearing (RT3D) replicates preferentially in Ras-activated cancers. RT3D shows synergistic in vitro cytotoxicity in combination with platins and taxanes. The purpose of this phase I/II study was to assess RT3D combined with ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e76955e6bfcd0182cc7f818311a2f32
https://doi.org/10.1158/1078-0432.ccr-11-2181

Zobrazit plný text záznamu

Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer

Autor: John D. Chester, Jackie Perry, Simon P. Joel, Christopher J. Button, Susan L. Cheeseman, Matthew T. Seymour, Theresa Davis, Geoffrey D. Hall, Michael Braun

Publikováno v: Journal of Clinical Oncology. 21:1125-1132

Purpose: To assess the safety and toxicity profile of escalating doses of intravenous irinotecan, in combination with a fixed dose of oral ciclosporin (Cs) and to determine the pharmacokinetic profile of irinotecan and its metabolites. Patients and M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f19a8f455727cabf91a3134d9b3b4330
https://doi.org/10.1200/jco.2003.08.049

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání